Featured Multi-Omics Solutions
Discover our leading high-throughput sequencing services integrated with mass spectrometry metabolomics workflows.
Mass Spectrometry-Based Metabolomics: Driving the Next Frontier in Multi-Omics Sequencing Services
In the modern biological and clinical research landscape, the integration of multi-omics techniques has transitioned from a cutting-edge luxury to an absolute necessity. Among these, Mass Spectrometry-Based Metabolomics stands out as the ultimate functional readout of cellular activity. By measuring the complete set of small-molecule metabolites within a biological system, metabolomics bridges the gap between genotype and phenotype. When combined with Next-Generation Sequencing (NGS) and third-generation long-read sequencing technologies, it provides researchers with an unprecedented, holistic understanding of biological mechanisms. This comprehensive guide explores the commercial landscape, industrial trends, and deep application scenarios where mass spectrometry-based metabolomics synergizes with high-throughput sequencing services to accelerate discovery in life sciences.
The Commercial and Industrial Landscape of Metabolomics & Sequencing
The global market for multi-omics services is experiencing exponential growth, driven by the demand for precision medicine, advanced agricultural biotechnology, and biomarker discovery. Historically, genomics and metabolomics operated in silos. DNA and RNA sequencing provided information on genetic potential and transcriptional activity, while mass spectrometry (MS) identified the downstream chemical substrates. Today, contract research organizations (CROs) and scientific service providers are increasingly offering integrated workflows that merge these datasets.
Industrially, the commercialization of high-resolution mass spectrometers—such as Quadrupole Time-of-Flight (Q-TOF) and Orbitrap systems—has enabled high-throughput, untargeted metabolomics at a scale compatible with NGS pipelines. The integration of these platforms allows biotech and pharmaceutical companies to accelerate drug discovery pipelines, validate therapeutic targets, and characterize drug mechanism of action (MoA) with high confidence. Consequently, sequencing service promotions that bundle metabolomics and proteomics alongside genomic services are capturing a larger share of the research market, offering clients a one-stop-shop for biological insight.
High-Resolution Analytics
Utilizing advanced Waters XEVO G2-XS QTOF and QTRAP 6500+ systems for ultra-sensitive metabolite detection and precise chemical profiling.
Multi-Omics Synergy
Seamlessly combining genomics, transcriptomics, proteomics, and metabolomics to map complete biological pathways.
AI Bioinformatics
Leveraging the BMKCloud platform with massive computing power for automated data alignment and metabolic pathway mapping.
Key Technological Trends Shaping the Future of Metabolomics
Several key developmental trends are currently reshaping how mass spectrometry-based metabolomics is utilized alongside sequencing services:
1. Spatial Metabolomics and Spatial Transcriptomics
Understanding where molecules reside within a tissue is as critical as knowing their abundance. Spatial metabolomics, utilizing Matrix-Assisted Laser Desorption/Ionization (MALDI) mass spectrometry imaging, is being paired with spatial transcriptomics (such as BMKGene's BMKMANU S3000 technology). This allows researchers to overlay metabolic changes directly onto histological tissue structures, providing a high-resolution map of cellular microenvironments in cancer, neuroscience, and plant biology.
2. Single-Cell Metabolomics
Similar to the revolution of single-cell RNA sequencing (scRNA-seq), single-cell metabolomics is emerging to resolve cellular heterogeneity. High-sensitivity mass spectrometry now enables the detection of primary metabolites within individual cells, helping to trace cellular differentiation, metabolic reprogramming in cancer stem cells, and cellular responses to environmental stressors.
3. Machine Learning and AI-Driven Data Integration
The bottleneck of untargeted metabolomics has long been metabolite identification. Advanced AI algorithms and neural networks are now deployed to predict spectral fragmentation patterns, align multi-omics datasets, and reconstruct metabolic networks. This computational power, combined with platforms like BMKCloud, dramatically reduces turnaround times and increases the accuracy of biological interpretations.
Deep-Dive Application Scenarios: Where Metabolomics Meets Genomics
Scenario A: Exosomal Biomarker Discovery & Diagnostics
Exosomes and other extracellular vesicles (EVs) play pivotal roles in intercellular communication, carrying selective payloads of small RNAs, proteins, and metabolites. By combining Exosomal Small RNA Sequencing with mass spectrometry-based lipidomics and metabolomics, researchers can identify robust biomarkers for early-stage cancer, neurodegenerative diseases, and cardiovascular conditions. Metabolomics reveals the immediate physiological state of the originating cells, while small RNA sequencing provides the regulatory context, together establishing a highly sensitive multi-marker diagnostic panel.
Scenario B: Metagenomics and Host-Microbiome Interactions
The gut microbiome influences human health by producing a vast array of bioactive metabolites, such as short-chain fatty acids (SCFAs), bile acids, and neurotransmitters. Standard Metagenomic sequencing (NGS) identifies "who is there" (microbial composition) and "what they can do" (functional genes). However, it cannot confirm "what they are actually doing." Mass spectrometry-based metabolomics directly measures the chemical output of the microbiome. Integrating metagenomics with metabolomics allows researchers to map specific bacterial strains to their metabolic products, paving the way for personalized nutrition, probiotics, and microbiome-targeted therapeutics.
Scenario C: Agricultural Biotechnology and Crop Resilience
In agriculture, developing crops that can withstand climate change, drought, and pests is a global priority. Through De Novo Genome Assembly and transcriptomics, scientists can identify resistance genes. When paired with untargeted metabolomics, they can observe the actual defense compounds (phytoalexins, flavonoids, terpenoids) synthesized by the plant under stress. This joint approach speeds up marker-assisted breeding and metabolic engineering, allowing for the design of high-yield, resilient crop varieties.
Scenario D: Pharmaceutical Target Validation & Synthetic Biology
In drug discovery, understanding how a small molecule affects the global metabolic network is vital for predicting efficacy and toxicity. Integrating proteomics and metabolomics helps map the interactions between proteins and metabolites. In synthetic biology, this multi-omics approach guides the optimization of metabolic pathways in host organisms (e.g., yeast or E. coli) for the bio-manufacturing of high-value chemicals, biofuels, and pharmaceuticals.
Technical Synergy: Integrating Mass Spectrometry with Next-Generation Sequencing
To maximize the value of sequencing services, service providers must offer robust multi-omics integration. The workflow begins with co-extraction protocols that isolate DNA, RNA, proteins, and metabolites from a single sample, minimizing biological noise and sample-to-sample variation. Following extraction, the genomic and transcriptomic components are analyzed using high-throughput sequencing platforms (such as Illumina NovaSeq or PacBio Sequel II), while the proteomic and metabolomic components are analyzed via LC-MS/MS (using systems like the Waters XEVO G2-XS QTOF or QTRAP 6500+).
The true power of this integration is realized during bioinformatic analysis. By correlating gene expression levels (transcriptomics) with metabolite abundances (metabolomics) using tools like Weighted Gene Co-expression Network Analysis (WGCNA) and metabolic pathway mapping (KEGG database), researchers can pinpoint the exact regulatory nodes governing a biological phenotype. This system-level view reduces false positives and provides a solid foundation for downstream functional validation.
Biomarker Technologies (BMKGene)
Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics. Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform. We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale.
Our Core Platforms
Advanced Sequencing Platforms
PacBio platforms: Sequel II, Sequel, RSII
Nanopore platforms: PromethION P48, GridION X5, MinION
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Illumina platforms: NovaSeq
BGI-sequencing platforms: DNBSEQ-G400, DNBSEQ-T7
Bionano Irys system
Waters XEVO G2-XS QTOF
QTRAP 6500+
State-of-the-Art Facilities
Over 20,000 square feet facility equipped with advanced biomolecular laboratory instruments. Standard labs for sample extraction, library construction, clean rooms, and sequencing labs operating under strict SOPs to ensure maximum sample integrity and data quality.
BMKCloud Bioinformatics
Self-developed, reliable, and easy-to-use online bioinformatics analysis platform. Supported by CPUs with 41,104 memory, 3 PB total storage, and 4,260 computing cores with peak computing power exceeding 121,708.8 Gflop per second.
Fully Automated Sequencing Production Line
Brilliant Lab 1000 (BL1000)
Biomarker Technologies (BMKGENE) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to high-throughput NGS library construction services.
BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, to provide customers with better sequencing services.
Our Advanced Production Facilities
Enterprise Qualifications & Joint Laboratories
Patents, Quality Certifications & Software Copyrights
